Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

Intellia Therapeutics (NTLA) said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.

The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.

Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.

Shares of the company were down by more than 20% in recent Thursday premarket activity.